Europe's biotech sector is being hit hard by the credit crunch, with small and medium-sized companies being starved of funding from venture capitalists.
As a result, Europe's dream to compete with the US biotech sector and create a heavyweight to rival Amgen or Genentech could be over, as increasing numbers of the continent's biotechs are bought out by big pharma.
More at Pharmafocus
No comments:
Post a Comment